Soluble Guanylate Cyclase - Pipeline Review, H2 2020
Soluble Guanylate Cyclase - Pipeline Review, H2 2020
SUMMARY
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H2 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 4, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Glaucoma, Coronavirus Disease 2019 (COVID-19), Pulmonary Arterial Hypertension, Diabetic Nephropathy, Lung Disease, Ocular Hypertension, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Chronic Thromboembolic Pulmonary Hypertension, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pneumonia, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Raynauds Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H2 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 4, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Glaucoma, Coronavirus Disease 2019 (COVID-19), Pulmonary Arterial Hypertension, Diabetic Nephropathy, Lung Disease, Ocular Hypertension, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Chronic Thromboembolic Pulmonary Hypertension, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pneumonia, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Raynauds Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
Appendix
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AntiRadical Therapeutics LLC, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Cyclerion Therapeutics Inc, H2 2020
Pipeline by Gurus BioPharm, H2 2020
Pipeline by NicOx SA, H2 2020
Pipeline by Nitric Oxide Innovations LLC, H2 2020
Pipeline by Novartis AG, H2 2020
Pipeline by Novoteris LLC, H2 2020
Pipeline by Toa Eiyo Ltd, H2 2020
Pipeline by Topadur Pharma AG, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AntiRadical Therapeutics LLC, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Cyclerion Therapeutics Inc, H2 2020
Pipeline by Gurus BioPharm, H2 2020
Pipeline by NicOx SA, H2 2020
Pipeline by Nitric Oxide Innovations LLC, H2 2020
Pipeline by Novartis AG, H2 2020
Pipeline by Novoteris LLC, H2 2020
Pipeline by Toa Eiyo Ltd, H2 2020
Pipeline by Topadur Pharma AG, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
